News

Robert Edwards, PhD, discusses how cognitive behavioral therapy effectively reduced pain catastrophizing and improved quality of life in patients with fibromyalgia.

Patients with RAO had a higher risk of death, stroke, and myocardial infarction at both short-term and long-term intervals compared to matched controls diagnosed with cataract.

In this interview, Dr. Kwatra explored the recent phase 3 data from the Olympia 2 study on nemolizumab treatment for patients with prurigo nodularis.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

The risk of fractures was 14% greater in the group with patients with the autoimmune disease than the control group.

A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared to those without IBS.

The FDA has expanded the approval of abatacept (Orencia) for the treatment of active psoriatic arthritis in patients aged 2 years and older.

A study from investigators in Italy sheds further light on the relationship between physical activity and diabetic polyneuropathy risk in patients with type 1 diabetes.

Marla Dubinsky, MD, discusses findings from the LUCENT program and their role in the recent FDA approval of mirikizumab for ulcerative colitis.

Ruth Napier, PhD, discusses her study revealing the crucial role the biomarker Card9 plays in the pathogenesis of ankylosing spondylitis.

12-month GATHER2 results show monthly avacincaptad pegol 2 mg was well tolerated and showed significantly slower geographic atrophy growth than sham treatment.

These new results highlight the importance of further examining the link between cyberbullying, social pressures, academic performance, and eczema.

Biosimilars can be considerably cheaper for patients compared with the reference drug. Test your knowledge of when reference products can be swapped for biosimilars with this quiz.

This new data highlights the value of proper counseling regarding possible adverse effects prior to initiation of treatment initiation with JAK inhibitors.

Results from both phase 2 trials were presented in poster abstracts at ACG 2023.

On October 27, 2023, the FDA warned consumers to stop using ophthalmic products from 6 brands, including CVS Health and Rite Aid, after investigators found bacterial contamination at a manufacturing facility.

Atrasentan demonstrated superiority versus placebo for reduction in proteinuria through 36 weeks.

In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.

This case report from Brady Pregerson, MD, features a woman in her mid-60s presenting to the ER with generalized weakness and dyspnea. Can you determine the correct diagnosis?

The introduction of an ICD-10 code specific to IgG4-Related Disease offers a promising opportunity to revolutionize patient care, enable more accurate diagnoses, and improve outcomes.

Kremer discusses new ad hoc findings from the phase 3 ENHANCE trial showing seladelpar's unique effect on pruritus in patients with PBC.

Scleral buckling without PPV is effective for most patients with retinal dialysis and shows a low rate of cataract formation.

This interview with Dr. Feldman involved a discussion on new findings regarding atopic dermatitis patient preferences and racial disparities in dermatologic care.

This endocrine case report from Brady Pregerson, MD features a 32-year-old female with a history of polycystic ovary syndrome and diabetes who presents to the emergency department for sudden trouble swallowing, confusion, and shakiness. Can you determine the correct diagnosis?

Most answers provided by ChatGPT-4 were consistently appropriate regarding vitreoretinal surgeries, including retinal detachments, macular holes, and epiretinal membranes.

In this interview with Dr. Steven Feldman, the latest findings on tralokinumab-ldrm as an atopic dermatitis treatment were discussed.

Guselkumab effectively cleared the skin of patients with moderate-to-severe plaque psoriasis across all skin tones, with significant improvements observed within the first 16 weeks of treatment.

Findings were presented in an abstract at ACG 2023, highlighting the importance of addressing bowel urgency in patients with ulcerative colitis.

Genentech announced the FDA had approved faricimab-svoa (Vabysmo) for retinal vein occlusion on October 26, 2023, which marks the third ophthalmic indication for the bispecific antibody.

New data from ACG 2023 shows etrasimod-treated patients were able to achieve UC remission, with or without concomitant steroid treatment at baseline.